Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin‐ethanolamides) in the feline iris

Identification of an antagonist that selectively blocks the activity of prostamides... Background and Purpose: The prostamides (prostaglandin‐ethanolamides) and prostaglandin (PG) glyceryl esters are biosynthesized by COX‐2 from the respective endocannabinoids anandamide and 2‐arachidonyl glycerol. Agonist studies suggest that their pharmacologies are unique and unrelated to prostanoid receptors. This concept was further investigated using antagonists. Experimental Approach: The isolated feline iris was used as a key preparation, where prostanoid FP receptors and prostamide activity co‐exist. Activity at human recombinant FP and other prostanoid receptors was determined using stable transfectants. Key Results: In the feline iris, AGN 204396 produced a rightward shift of the dose‐response curves for prostamide F2α and the prostamide F2α analog bimatoprost but did not block the effects of PGF2α and synthetic FP receptor agonists. Studies on human recombinant prostanoid receptors confirmed that AGN 204396 did not behave as a prostanoid FP receptor antagonist. AGN 204396 exhibited no antagonism at DP and EP1‐4, but was a highly effective TP receptor antagonist. Contrary to expectation, the FP receptor antagonist AL‐8810 efficaciously contracted the cat iris. AGN 204396 did not affect AL‐8810 induced contractions, demonstrating that AL‐8810 and AGN 204396 are pharmacologically distinct. Unlike AL‐8810, the ethylamide derivate of AL‐8810 was not an agonist. Al‐8810 did not block prostamide F2α activity. Finally, AGN 204396 did not block PGE2‐glyceryl ester activity. Conclusions and Implications: The ability of AGN 204396 to selectively block prostamide responses suggests the existence of prostamide sensitive receptors as entities distinct from receptors recognizing PGF2α and PGE2‐glyceryl ester. British Journal of Pharmacology (2007) 150, 342–352. doi:10.1038/sj.bjp.0706989 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Pharmacology Wiley

Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin‐ethanolamides) in the feline iris

Download PDF
11 pages
Read Article

Loading next page...
 
/lp/wiley/identification-of-an-antagonist-that-selectively-blocks-the-activity-twDcaXSBcD
Publisher
Wiley
Copyright
2007 British Pharmacological Society
ISSN
0007-1188
eISSN
1476-5381
DOI
10.1038/sj.bjp.0706989
pmid
17179945
Publisher site
See Article on Publisher Site

Abstract

Background and Purpose: The prostamides (prostaglandin‐ethanolamides) and prostaglandin (PG) glyceryl esters are biosynthesized by COX‐2 from the respective endocannabinoids anandamide and 2‐arachidonyl glycerol. Agonist studies suggest that their pharmacologies are unique and unrelated to prostanoid receptors. This concept was further investigated using antagonists. Experimental Approach: The isolated feline iris was used as a key preparation, where prostanoid FP receptors and prostamide activity co‐exist. Activity at human recombinant FP and other prostanoid receptors was determined using stable transfectants. Key Results: In the feline iris, AGN 204396 produced a rightward shift of the dose‐response curves for prostamide F2α and the prostamide F2α analog bimatoprost but did not block the effects of PGF2α and synthetic FP receptor agonists. Studies on human recombinant prostanoid receptors confirmed that AGN 204396 did not behave as a prostanoid FP receptor antagonist. AGN 204396 exhibited no antagonism at DP and EP1‐4, but was a highly effective TP receptor antagonist. Contrary to expectation, the FP receptor antagonist AL‐8810 efficaciously contracted the cat iris. AGN 204396 did not affect AL‐8810 induced contractions, demonstrating that AL‐8810 and AGN 204396 are pharmacologically distinct. Unlike AL‐8810, the ethylamide derivate of AL‐8810 was not an agonist. Al‐8810 did not block prostamide F2α activity. Finally, AGN 204396 did not block PGE2‐glyceryl ester activity. Conclusions and Implications: The ability of AGN 204396 to selectively block prostamide responses suggests the existence of prostamide sensitive receptors as entities distinct from receptors recognizing PGF2α and PGE2‐glyceryl ester. British Journal of Pharmacology (2007) 150, 342–352. doi:10.1038/sj.bjp.0706989

Journal

British Journal of Pharmacology – Wiley

Published: Feb 1, 2007

References

  • Some quantitative use of drug antagonists
    Arunlakshana, Arunlakshana; Schild, Schild
  • Investigation of structural analogs of prostaglandin amides for binding to and activation of CB and CB 2 cannabinoid receptors in rat brain and human tonsils
    Berglund, Berglund; Boring, Boring; Howlett, Howlett
  • Oxidative metabolism of anandamide
    Burstein, Burstein; Rossetti, Rossetti; Yagen, Yagen; Zurier, Zurier
  • Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles
    Chen, Chen; Senior, Senior; Marshall, Marshall; Abbas, Abbas; Dinh, Dinh; Dinh, Dinh
    Bookmark
  • Prostanoid receptors: the development of a working classification
    Coleman, Coleman; Humphrey, Humphrey; Kennedy, Kennedy; Lumley, Lumley
  • Efficacy and safety of bimatoprost in patients with elevated intraocular pressure
    Dubiner, Dubiner; Cooke, Cooke; Dirks, Dirks; Stewart, Stewart; Vandenburgh, Vandenburgh; Felix, Felix
    Bookmark
  • Effect of bimatoprost on patients with primary open‐angle glaucoma on ocular hypertension who are nonresponders to latanoprost
    Gandolfi, Gandolfi; Cimino, Cimino
  • Misidentification of prostamides as prostaglandins
    Glass, Glass; Hong, Hong; Sato, Sato; Mitchell, Mitchell
  • AL‐8810: a novel prostaglandin F 2 analog with selective antagonist effects at the prostaglandin F 2 (FP) receptor
    Griffin, Griffin; Klimko, Klimko; Crider, Crider; Sharif, Sharif
  • One‐year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension
    Higginbotham, Higginbotham; Schuman, Schuman; Goldberg, Goldberg; Gross, Gross; Vandenburgh, Vandenburgh; Chen, Chen
  • Preliminary studies using a putative FP‐receptor antagonist, AL‐8810, on isolated mouse uterus
    Hutchinson, Hutchinson; Marshall, Marshall; Senior, Senior
  • Real‐time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors
    Kelly, Kelly; Williams, Williams; Sharif, Sharif
  • Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of bimatoprost as a potent inhibitor of the enzyme: new enzyme method by LC/GSI/MS
    Koda, Koda; Tsutsui, Tsutsui; Niwa, Niwa; Ito, Ito; Woodward, Woodward; Watanabe, Watanabe
  • Metabolism of the endocannabinoids, 2‐arachidonylglycerol and anandamide, into prostaglandin, thromboxane and prostacyclin glycerol esters and ethanolamides
    Kozak, Kozak; Crews, Crews; Morrow, Morrow; Wang, Wang; Ma, Ma; Weinander, Weinander
  • Metabolism of prostaglandin glyceryl esters and prostaglandin ethanolamides in vitro and in vivo
    Kozak, Kozak; Crews, Crews; Ray, Ray; Tai, Tai; Morrow, Morrow; Marnett, Marnett
  • Upregulation of orphan nuclear receptor Nur 77 following PGF 2 , bimatoprost and butaprost treatments. Essential role of a protein kinase C pathway involved in the EP 2 receptor activated Nur 77 gene transcription
    Liang, Liang; Li, Li; Guzman, Guzman; Chang, Chang; Evinger, Evinger; Pablo, Pablo
  • Comparison of PGF 2 , bimatoprost (prostamide) and butaprost (EP 2 agonist) on Cyr 61 and CTGF gene expression
    Liang, Liang; Li, Li; Guzman, Guzman; Evinger, Evinger; Protzman, Protzman; Krauss, Krauss
  • Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism
    Matias, Matias; Chen, Chen; Petrocellis, Petrocellis; Bisogno, Bisogno; Ligresti, Ligresti; Fezza, Fezza
  • The glyceryl ester of prostaglandin E 2 mobilizes calcium and activates signal transduction in RAW 264.7 cells
    Nirodi, Nirodi; Crews, Crews; Kozak, Kozak; Morrow, Morrow; Marnett, Marnett
  • A six‐month randomized clinical trail comparing the intraocular pressure lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma
    Noecker, Noecker; Dirks, Dirks; Choplin, Choplin; Bernstein, Bernstein; Batoosingh, Batoosingh; Whitcup, Whitcup
  • A cyclooxygenase metabolite of anandamide causes inhibition of interleukin‐2 secretion in murine splenocytes
    Rockwell, Rockwell; Kaminski, Kaminski
  • Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E 2 ethanolamide
    Ross, Ross; Craib, Craib; Stevenson, Stevenson; Pertwee, Pertwee; Henderson, Henderson; Toole, Toole
  • Bimatoprost and its free acid are prostaglandin FP receptor agonists
    Sharif, Sharif; Williams, Williams; Kelly, Kelly
    Bookmark
  • Bimatoprost and prostaglandin F 2 selectively stimulate intracellular calcium signaling in different cat iris sphincter cells
    Spada, Spada; Krauss, Krauss; Woodward, Woodward; Chen, Chen; Protzman, Protzman; Nieves, Nieves
  • Formation of prostaglandin 1‐ethanolamides (prostamides) from anandamide in fatty acid amide hydrolose knockout (FAAH −/−) mice analyzed by high performance liquid chromatography with tandem mass spectrometry
    Weber, Weber; Ni, Ni; Ling, Ling; Acheampong, Acheampong; Tang‐Liu, Tang‐Liu; Cravatt, Cravatt
  • The pharmacology of bimatoprost (Lumigan™)
    Woodward, Woodward; Krauss, Krauss; Chen, Chen; Lai, Lai; Spada, Spada; Burk, Burk
  • Pharmacological characterizations of a novel antiglaucoma agent, bimatoprost (AGN 192024)
    Woodward, Woodward; Krauss, Krauss; Chen, Chen; Liang, Liang; Li, Li; Protzman, Protzman
  • Bimatoprost: a novel anti‐glaucoma agent
    Woodward, Woodward; Phelps, Phelps; Krauss, Krauss; Weber, Weber; Short, Short; Chen, Chen
  • Synthesis of prostaglandin E 2 ethanolamide from anandamide by cyclooxygenase‐2
    Yu, Yu; Ives, Ives; Ramesha, Ramesha

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

Sign up
for free
Start 14 day
Free Trial